Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
COWS is a structured withdrawal severity tool that combines observed and reported symptoms to classify opioid withdrawal intensity and support treatment planning in supervised settings.
Formula: COWS total = sum of 11 domain scores (range 0-48).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The COWS combines clinician observation with patient self-report across 11 items covering both autonomic and subjective opioid withdrawal manifestations. Observed items: resting pulse rate, sweating, pupil size, tremor, yawning, and gooseflesh (piloerection). Patient-reported items: restlessness, bone/joint aches, runny nose/tearing, GI upset, and anxiety/irritability. Each item uses a specific scoring range (0-3, 0-4, or 0-5) with anchored descriptors. Pupil dilation is a particularly reliable objective marker — opioid withdrawal causes parasympathetic rebound and marked mydriasis.
After assessing all 11 items, sum the individual scores to produce a total between 0 and approximately 48 (maximum varies slightly by version). Reassessment frequency depends on severity and clinical context — typically every 4-8 hours during active withdrawal, and more frequently around the time of planned buprenorphine induction (every 1-2 hours). Document the time of each assessment and any medications given, as COWS scores are used to trigger and titrate treatment interventions.
Mild withdrawal (COWS 5-12): patient is in early withdrawal — monitor closely; buprenorphine induction may proceed at COWS 8-12. Moderate withdrawal (COWS 13-24): pharmacotherapy indicated; buprenorphine induction typically safe. Moderately severe withdrawal (COWS 25-36): medication required. Severe withdrawal (COWS above 36): indicates severe dependence and high medication need. Critical rule: do not administer buprenorphine if COWS is below 8, as precipitated withdrawal can occur when the patient has significant residual opioids occupying receptors.
Addiction Medicine Specialists
COWS is the standard monitoring tool for opioid withdrawal in inpatient detoxification settings. Serial COWS assessments track symptom trajectory, guide alpha-2 agonist (clonidine) or opioid agonist dosing, and determine discharge readiness based on symptom resolution.
Buprenorphine Prescribers
The most critical application of COWS is determining when it is safe to administer the first dose of buprenorphine. A COWS score of 8-12 or above is typically required before induction to avoid precipitated withdrawal from buprenorphine displacing full opioid agonists.
Methadone Counselors
Opioid treatment programs (OTPs) use COWS to assess withdrawal severity in patients during observed dosing, to document adequate withdrawal before first methadone dose, and to monitor patients during dose adjustments or interruptions in methadone access.
Emergency Physicians
Emergency departments increasingly initiate buprenorphine for patients presenting in opioid withdrawal. COWS provides the objective documentation of withdrawal severity needed to justify buprenorphine induction in the ED and creates a baseline for outpatient MOUD continuation.
Researchers
The COWS is used as a standardized outcome measure in opioid use disorder clinical trials to quantify withdrawal severity during detoxification and to document successful buprenorphine or methadone induction. Its 0-48 continuous scale enables quantitative between-group comparisons.
MOUD Providers
Medications for opioid use disorder (MOUD) programs use COWS to assess readiness for buprenorphine/naloxone (Suboxone) induction, guiding the timing of first dosing and documenting clinical necessity for insurance authorization and regulatory compliance.
Buprenorphine is a partial opioid agonist with very high mu-receptor affinity. When administered to a patient who still has significant full opioid agonists (heroin, oxycodone, methadone) occupying receptors without being in withdrawal, buprenorphine rapidly displaces them, causing an immediate, severe withdrawal syndrome (precipitated withdrawal). To prevent this, the patient must be in objective withdrawal — COWS 8-12 or above — before the first buprenorphine dose. Always confirm that COWS is at threshold before administering the first dose.
Precipitated opioid withdrawal from premature buprenorphine induction is characterized by sudden, intense, all-body withdrawal symptoms — severe muscle aches, restlessness, diaphoresis, nausea, vomiting, and extreme dysphoria — that begin within minutes of buprenorphine dosing and can last several hours. Unlike gradual spontaneous withdrawal, precipitated withdrawal onset is abrupt and the severity peaks rapidly. It is not life-threatening but is extremely distressing and can severely damage patient trust and willingness to continue MOUD. Prevention by ensuring adequate COWS score before induction is essential.
If a patient presents requesting buprenorphine but their COWS score is below 8, do not administer the first dose. Educate the patient about why waiting is important, reassess every 1-2 hours, and initiate when COWS reaches threshold. In urgent situations where the patient cannot wait, consider low-dose buprenorphine induction (micro-dosing/LDEI) protocols that circumvent the need for full withdrawal onset.
The dominance of illicit fentanyl in the opioid supply has significantly complicated buprenorphine induction. Fentanyl is highly lipophilic and accumulates in body fat, resulting in prolonged tissue binding and slow release that can make patients appear to have lower COWS scores than their actual receptor occupancy warrants. Patients using fentanyl may need a COWS score of 12-16 or above before induction is safe, or may benefit from extended waiting periods (24-48 hours or longer) or low-dose induction protocols.
The low-dose buprenorphine induction (LDEI) protocol, also called 'micro-dosing' or the Bernese method, administers very small doses of buprenorphine (0.5-2mg) daily while the patient is still on full opioid agonists, gradually increasing the dose over 5-7 days until full buprenorphine doses can be given. This approach avoids precipitated withdrawal and is particularly valuable for patients on methadone or high-dose fentanyl where standard induction timelines are impractical.
The Mainstreaming Addiction Treatment (MAT) Act, included in the Consolidated Appropriations Act of 2023, eliminated the requirement for a special DEA X-waiver (DATA 2000) to prescribe buprenorphine for opioid use disorder. Any DEA-registered healthcare provider can now prescribe buprenorphine/naloxone (Suboxone) in an office-based setting. This removes a major barrier to expanding MOUD access. Emergency physicians, hospitalists, and primary care providers are now empowered to initiate buprenorphine without special certification.
Methadone for opioid use disorder must be dispensed daily in federally licensed opioid treatment programs (OTPs). Unlike buprenorphine, which can be prescribed by any DEA-registered provider for take-home use, methadone for OUD has strict federal regulatory requirements. COWS monitoring is used in OTPs to assess patient withdrawal status, guide initial dose, and monitor clinical status during dose adjustments. Extended-release naltrexone (Vivitrol) is a third MOUD option requiring full opioid detoxification (7+ days off all opioids) before initiation.
Alpha-2 agonists like clonidine are frequently used to reduce autonomic opioid withdrawal symptoms (diaphoresis, elevated pulse, hypertension, restlessness) captured by COWS items. Clonidine is not FDA-approved for OUD treatment but is commonly used during medically supervised withdrawal as an adjunct or in settings where buprenorphine or methadone are not immediately available. COWS monitoring during clonidine treatment documents symptom response. Clonidine does not reduce opioid craving and has no evidence for preventing relapse, making it inferior to MOUD for long-term outcomes.
COWS published by Wesson and Ling (J Psychoactive Drugs 2003). COWS validated for opioid withdrawal severity and buprenorphine induction timing. Buprenorphine induction threshold COWS 8-12: SAMHSA TIP 63 (2021). Precipitated withdrawal mechanism and prevention: Bao et al. (Curr Psychiatry Rep 2021). DEA X-waiver removal: Mainstreaming Addiction Treatment (MAT) Act 2023. Low-dose buprenorphine induction: Herring et al. (Ann Emerg Med 2019). Extended-release naltrexone for OUD: Lee et al. (Lancet 2018).
Higher COWS totals indicate more severe opioid withdrawal symptoms and support escalation of supervised withdrawal management intensity.
Use in monitored opioid withdrawal settings to trend symptom burden and support treatment timing and reassessment decisions.
Symptoms can overlap with anxiety, infection, stimulant effects, and other medical conditions, so the score should be interpreted within full clinical context.
For related assessments, see Opioid Risk Tool, Opioid MME and POSS Scale.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Screen risk of opioid misuse with the Opioid Risk Tool before initiating long-term opioid therapy.
OpenPharmacyCalculate morphine milligram equivalents (MME) for opioid medications using CDC conversion factors. ≥50 MME/day warrants caution; ≥90 MME/day carries significantly increased overdose risk.
OpenPharmacyClassify opioid-related sedation severity (S, 1, 2, 3, 4) and map to common bedside action guidance.
Open